Abstract
The Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) created psychosis Biotypes based on neurobiological measurements in a multi-ancestry sample. These Biotypes cut across DSM diagnoses of schizophrenia, schizoaffective disorder and bipolar disorder with psychosis. Two recently developed post hoc ancestry adjustment methods of Polygenic Risk Scores (PRSs) generate Ancestry-Adjusted PRSs (AAPRSs), which allow for PRS analysis of multi-ancestry samples. Applied to schizophrenia PRS, we found the Khera AAPRS method to show superior portability and comparable prediction accuracy as compared with the Ge method. The three Biotypes of psychosis disorders had similar AAPRSs across ancestries. In genomic analysis of Biotypes, 12 genes and isoforms showed significant genomic associations with specific Biotypes in Transcriptome-Wide Association Study (TWAS) of genetically regulated expression (GReX) in adult brain and fetal brain. TWAS inflation was addressed by inclusion of genotype principal components in the association analyses. Seven of these 12 genes/isoforms satisfied Mendelian Randomization (MR) criteria for putative causality, including four genes TMEM140, ARTN, C1orf115, CYREN, and three transcripts ENSG00000272941, ENSG00000257176, ENSG00000287733. These genes are enriched in the biological pathways of Rearranged during Transfection (RET) signaling, Neural Cell Adhesion Molecule 1 (NCAM1) interactions, and NCAM signaling for neurite out-growth. The specific associations with Biotypes suggest that pharmacological clinical trials and biological investigations might benefit from analyzing Biotypes separately.
Competing Interest Statement
Cuihua Xia: None. Ney Alliey-Rodriguez: None. Carol A. Tamminga: B-SNIP Diagnostics, Board of Managers; Kynexis, Scientific Advisory Board and retainer; Merck DSMB; Neuventis, Board, own stock. Matcheri S. Keshavan: B-SNIP Diagnostics, Board of Managers; Advisor to Alkermes. Godfrey D. Pearlson: B-SNIP Diagnostics, Board of Managers. Sarah K. Keedy: B-SNIP Diagnostics, Board of Managers. Brett A. Clementz: B-SNIP Diagnostics, Board of Managers; Kynexis Corporation, Scientific Advisory Board. Jennifer E. McDowell: B-SNIP Diagnostics, Board of Managers. David A. Parker: None. Rebekka Lencer: None. S. Kristian Hill: None. Jeffrey R. Bishop: None. Elena I. Ivleva: B-SNIP Diagnostics, Board of Managers. Cindy Wen: None. Rujia Dai: None. Chao Chen: None. Chunyu Liu: None. Elliot S. Gershon: B-SNIP Diagnostics, Board of Managers; Consultant: Kynexis Corporation.
Funding Statement
This research was supported by several NIH grants: Tamminga: MH096913, MH077851. Pearlson: MH096957, MH077945. Keshavan: MH096942, MH078113. Keedy: MH103368, MH124804, MH127162. Clementz: MH124803, MH126398, MH096900, MH124806, MH103366, MH124802, MH127172. Parker: NIH/NIMH R01MH117315 and NIH/NCATS UL1TR002378, TL1TR002382. Liu: U01 MH122591, 1U01MH116489, 1R01MH110920, R01MH126459. Gershon: MH103368, MH124804, MH127162. This research was also supported by the National Natural Science Foundation of China (Grants Nos. 82022024), and the science and technology innovation Program of Hunan Province (2021RC4018, 2021RC5027). Innovation-driven Project of Central South University (Grant No. 2020CX003). The authors gratefully acknowledge support from the Christopher Eklund family and the Geraldi Norton Foundation. We thank Drs Tian Ge and Hailiang Huang for their correspondence and support about PRS post hoc ancestry adjustment. This work was completed in part with resources provided by the University of Chicago's Research Computing Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All methods were performed in accordance with the relevant guidelines and regulations. B-SNIP recruitment sites were in Athens GA (University of Georgia and Augusta University Medical College of Georgia), Baltimore MD (Maryland Psychiatric Research Center), Boston MA (Beth Israel Deaconess Medical Center), Chicago IL (University of Illinois-Chicago and University of Chicago), Dallas TX (UT Southwestern Medical Center), Detroit MI (Wayne State University), and Hartford CT (Institute of Living). All recruitments, interviews, and laboratory data collections were completed at those locations. The Institutional Review Board at participating institutions approved the projects; participants provided informed consent prior to involvement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
